Ulrik Bak Dragsted

Ulrik Bak Dragsted

Auto-generated profile, based on publicly available information

Ulrik Bak Dragsted

Hvidovre University Hospital, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
UDUlrik Bak Dragsted
Ulrik Bak Dragsted
JGJan Gerstoft
Jan Gerstoft
CPCourt Pedersen
Court Pedersen
BPBarry Peters
Barry Peters
ADAdriana Duran
Adriana Duran
JLJens Lundgren
Jens Lundgren
This trial assessed the rate of virological failure at 48 weeks in adult human immunodeficiency virus (HIV) type 1–infected patients assigned indinav

1 July 2004 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
UDUlrik Bak Dragsted
Ulrik Bak Dragsted
AMAmanda Mocroft
Amanda Mocroft
SVStefano Vella
Stefano Vella
JVJean‐Paul Viard
Jean‐Paul Viard
AHAnn‐Britt E. Hansen
Ann‐Britt E. Hansen
SMStephan S. Monroe
Stephan S. Monroe
In 2002, a sharp increase in outbreaks of norovirus-associated illness, both on cruise ships and on land, encouraged us to examine the molecular epidemiology of detected noroviruses, to identify a common strain or source. Of 14 laboratory-confirmed outbreaks on cruise ships, 12 (86%) were attributed to caliciviruses; among these 12, outbreak characteristics included continuation on successive cruises in 6 (50%), multiple modes of transmission in 7 (58%), and high (110%) attack rates in 7 (58%). Eleven of the 12 calicivirus outbreaks were attributed to noroviruses, 7 (64%) of which were attributed to a previously unreported lineage, provisionally named “the Farmington Hills strain.” From May 2002 to December 2002, 10 (45%) of 22 land-based outbreaks also were attributed to this strain. Nucleotide-sequence analysis provided insights into norovirus transmission, by documenting links among outbreaks, the introduction of strains onto ships, and viral persistence on board (despite cleaning). Control measures for outbreaks should address all routes of transmission. Better outbreak surveillance and collection of data on sequences will help to monitor norovirus strains and to identify common sources.

1 August 2005 in Antiviral Therapy
Verified
Journal Article
Closed access
WBW Belloso
W Belloso
SIS Ivalo
S Ivalo
DPD Pugliese
D Pugliese
DGD Garone
D Garone
PCP Cahn
P Cahn
JLJens Lundgren
Jens Lundgren
Objective: To assess the rate of protocol-defined treatment failure and safety of lopinavir/ritonavir (LPV/r) and saquinavir/ritonavir (SAQ/r). Design: Open-label, prospective, randomized (1:1), international multi-centre trial. Methods: Adult HIV-1-infected patients were assigned LPV/r 400/100 mg twice daily or SAQ/r 1000/100 mg twice daily with two or more nucleoside reverse transcriptase inhibitors (NRTIs)/non-NRTIs. All patients, whether on or off the assigned treatment, were followed for 48 weeks. Results: Of 339 randomized patients, 324 initiated assigned treatment (intention-to-treat/exposed [ITT/e] population). At 48 weeks, treatment failure occurred in 29/163 (18%) and 53/161 (33%) of patients in the LPV/r and SAQ/r arms, respectively (ITT/e, P=0.002, log rank test). In an analysis that also considered those patients who discontinued treatment as having failed treatment (ITT/e/discontinuation=failure), 40/161 (25%) LPV/r-treated individuals versus 63/161 (39%) SAQ/R-treated individuals failed treatment ( P=0.005, log rank test). Discontinuation of the assigned treatment occurred in 23/163 (14%) patients in the LPV/r-treated group, compared with 48/161 (30%) in the SAQ/r-treated group (ITT/e; P=0.001). The primary reasons for premature discontinuation were non-fatal adverse events (LPV/r: 12/163; SAQ/r: 21/161) and patients’ choice (LPV/r: 7/163; SAQ/r: 8/161). In the on-treatment analysis of time to treatment failure, no difference was observed between the two arms ( P=0.27, log rank test). Conclusion: LPV/r had better antiretroviral effects compared with SAQ/r at the doses and in the formulations studied. This may have been a result of patients’ preferences and ability to adhere to assigned therapy, rather than a result of differences in the intrinsic potency of the study protease inhibitors.

22 April 2002
Verified
Journal Article
Closed access
UDUlrik Bak Dragsted
Ulrik Bak Dragsted
TBThomas L Benfield
Thomas L Benfield